Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocuronium allergy skin testing with sugammadex
ACTRN12610000707066Phase 4Not yet recruiting
- Sponsor
- Sir Charles Gairdner Hospital
- Start
- Oct 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rocuronium and Sugammadex in drug allergy, sponsored by Sir Charles Gairdner Hospital. Primary endpoint: Negative skin test with rocuronium plus sugammadex. Planned start Oct 2010; status: not yet recruiting.
02
Drugs
rocuroniumSugammadex
03
Conditions
drug allergy
Beyond the preview
Go deeper on ACTRN12610000707066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000707066.